ATC Group: M01CB03 Auranofin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M01CB03 in the ATC hierarchy

Level
Code
Title
1
Musculo-skeletal system
2
Antiinflammatory and antirheumatic products
3
Specific antirheumatic agents
4
Gold preparations
5
M01CB03
Auranofin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
6 mg

Active ingredients in M01CB03

Active Ingredient
Description

Auranofin is an orally available compound, used to treat rheumatoid arthritis, with anti-inflammatory activities. The main mechanism of action of auranofin is through the inhibition of reduction/oxidation (redox) enzymes such as thioredoxin reductase (TrxR). The thiol ligand contained in auranofin has a high affinity for thiol and selenol groups, to which it forms stable, and irreversible, adducts. Redox enzymes such as TrxR are essential to many cellular processes, particularly in maintaining the intracellular levels of reactive oxygen species (ROS).

Medicines in this ATC group

Drug
Countries

Australia Canada South Africa United States